Andere Sprachen Delta-Fly Pharma, Inc.

Aktien

A2PAFQ

JP3549370009

4598

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 02.05.2024			% 5 Tage	% 1. Jan.
739 ^JPY	+1.23%		-5.01%	-27.19%

08.04.	Delta-Fly Pharma Inc. erhält Zulassungsbescheid für die Durchführung der Phase I/II-Studie von DFP-10917 in Kombination mit Venetoclax	CI
11.03.	Delta-Fly Pharma Inc. gibt die Einreichung des Protokolls der Phase I/II-Studie von DFP-10917 in Kombination mit Venetoclax (VTX) bei AML-Patienten vor der Behandlung mit VTX bei der FDA bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax	08.04.
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	08.04.
Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen	11.03.
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	11.03.
Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting	07.02.
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting	07.02.
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323	02.02.
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323	02.02.
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML	30.01.
Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML	05.01.
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.	10.11.
Delta-Fly Pharma Inc.: Schedule for the Interim Analysis of the Phase 3 study of DFP-10917 in R/R AML	30.06.23
Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917	07.12.22
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited	05.12.22
Delta-Fly Pharma, Inc. announced that it expects to receive Ã‘1.300842 billion in funding from Macquarie Group Limited	17.11.22
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	24.12.20
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	08.12.20
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa	24.03.20
Delta-Fly Pharma, Inc. : Initiated Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927	26.11.19
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927	26.11.19

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Delta-Fly Pharma, Inc.

Aktien

A2PAFQ

JP3549370009

4598

Andere Sprachen

Filter